The Vienna based biotech company APEIRON Biologics AG supports the clinical development of an immune therapy against high-risk neuroblastoma in paediatric patients that is being conducted by the CCRI and the European Neuroblastoma Research Network SIOPEN at numerous European centres.
Downloads
Related Links
